Spero Therapeutics Inc expected to post a loss of 33 cents a share - Earnings Preview

Spero Therapeutics

10/05/2023 03:04

* Spero Therapeutics Inc  SPRO.OQ   SPRO.O  is expected
to show a
fall in quarterly revenue when it reports  results on May 11. 
    * The Cambridge Massachusetts-based  company is expected to
report
 a 51.7% decrease in revenue to $1 million from $2.07 million a
year ago, according to the mean estimate from 2 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Spero Therapeutics
Inc is
for a loss of 33 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Spero
Therapeutics Inc is $6​, above​ its last closing price of $1.94.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022              0.04       0.55      Beat    1,169.
                                                        3
 Sep. 30 2022  -0.31       -0.30      -0.33     Missed  -8.8
 Jun. 30 2022  -0.92       -0.93      -0.87     Beat    6.1​
 Mar. 31 2022  -0.86       -0.87      -1.01     Missed  -16.2
 ​​Dec.        -0.78       -0.75      -0.90     Missed  -20.4
 31 2021                                                
 Sep. 30 2021  -0.64       -0.66      -0.70     Missed  -5.5​
 Jun. 30 2021  -0.74       -0.75      -0.63     Beat    16.1
 Mar. 31 2021  -0.64       -0.64      -0.66     Missed  -2.3
 This summary was machine generated May 10 at 02:03 GMT.  All
figures in US dollars  unless otherwise stated